Patients Enrollment completed in Clinical Study on Propionyl-L-Carnitine Tablets for treatment of Peripheral Arterial Diseases

Hong Kong, July 2, 2010—Lee’s Pharmaceutical Holdings Limited (Main Broad Stock: 950: Website: www.leespharm.com) today announced that the Group has successfully reached the targeted patient enrollment for its clinical trial conducted in China on Sigma-Tau’s original product, Dromos® (Propionyl-L-Carnitine hydrochloride tablets, “PLC”), evaluating the effectiveness and safety for treatment of peripheral arterial diseases (intermittent claudication) in Chinese patients.

The release as fetched from its publisher. leespharm.com ↗